Influence of post-treatment delay on the evaluation of the response to focused ultrasound surgery of breast cancer by dynamic contrast enhanced MRI.

The assessment of the effectiveness of MRI-guided focused ultrasound surgery (MRIgFUS) of breast carcinomas can be performed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters which monitor the presence of residual tumour. The aim of this study was to evaluate the effect of the post-treatment delay on this assessment. DCE-MRI data were acquired immediately and 3-14 days after MRIgFUS treatment of 26 tumours (<7 days, n = 6; = or > ge;7 days, n = 20). The percentage of residual tumour was determined histologically on the resected mass and correlated with two DCE-MRI parameters: increase in signal intensity (ISI) and positive enhancement integral (PEI). No correlation could be found between DCE-MRI data acquired immediately after treatment and the percentage of residual tumour. Good correlation coefficients were found for data acquired several days after treatment (ISI, r = 0.749; PEI, r = 0.778). However, they were higher when the post-treatment time interval was 7 days or more (ISI, r = 0.962; PEI, r = 0.934). These results suggest that a post-treatment delay of 7 days is necessary for the accurate assessment of the presence of residual tumour by DCE-MRI parameters.

[1]  S. Heywang-Köbrunner,et al.  Contrast‐Enhanced MRI of the Breast after Limited Surgery and Radiation Therapy , 1993, Journal of computer assisted tomography.

[2]  D. Gianfelice,et al.  MR imaging-guided focused US ablation of breast cancer: histopathologic assessment of effectiveness-- initial experience. , 2003, Radiology.

[3]  Matthias David,et al.  Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. , 2003, American journal of obstetrics and gynecology.

[4]  D M Shames,et al.  Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.

[5]  O. Haraldseth,et al.  New intravascular contrast agent applied to dynamic contrast enhanced MR imaging of human breast cancer. , 2003, Acta radiologica.

[6]  D. Gianfelice,et al.  MR Imaging-guided Focused Ultrasound Surgery of Breast Cancer: Correlation of Dynamic Contrast-enhanced MRI with Histopathologic Findings , 2003, Breast Cancer Research and Treatment.

[7]  L. Turnbull,et al.  Dynamic contrast‐enhanced MRI in the differentiation of breast tumors: User‐defined versus semi‐automated region‐of‐interest analysis , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  J A de Zwart,et al.  Thermal therapies in interventional MR imaging. Focused ultrasound. , 2001, Neuroimaging clinics of North America.

[9]  D B Kopans,et al.  Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.

[10]  A R Padhani,et al.  Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.

[11]  G P Liney,et al.  Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI. , 2004, Breast.

[12]  F A Jolesz,et al.  MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. , 2001, Radiology.

[13]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[14]  J. Debus,et al.  A new noninvasive approach in breast cancer therapy using magnetic resonance imaging-guided focused ultrasound surgery. , 2001, Cancer research.

[15]  J. Schmee.  Applied Statistics—A Handbook of Techniques , 1984 .

[16]  J. M. Pruneda,et al.  Detection with MR imaging of residual tumor in the breast soon after surgery. , 1997, AJR. American journal of roentgenology.

[17]  Kullervo Hynynen,et al.  MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. , 2003, Radiology.

[18]  D. Fraker,et al.  Breast carcinoma: MR imaging before re-excisional biopsy. , 1997, Radiology.

[19]  M D Schnall,et al.  Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. , 1994, Radiology.

[20]  Sharon L. Thomsen,et al.  Mapping of thermal injury in biologic tissues using quantitative pathologic techniques , 1999, Photonics West - Biomedical Optics.

[21]  P J Drew,et al.  Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[23]  A. Heinig,et al.  Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy , 1998, Magnetic Resonance Materials in Physics, Biology and Medicine.

[24]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[25]  D. Gianfelice,et al.  Feasibility of magnetic resonance imaging-guided focused ultrasound surgery as an adjunct to tamoxifen therapy in high-risk surgical patients with breast carcinoma. , 2003, Journal of vascular and interventional radiology : JVIR.

[26]  L. Esserman,et al.  MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. , 2000, AJR. American journal of roentgenology.

[27]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[28]  S Yoshida,et al.  Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. , 1999, Oncology reports.